Ikarovec Secures Exclusive Option for VectorBuilder's Novel AAV Capsid Technology in $1B+ Deal for AMD Gene Therapy
Key Insights
Ikarovec (search) has entered an exclusive worldwide option agreement with VectorBuilder (search) for novel AAV capsid technology to enable office-based intravitreal delivery of IKAR-003 (search) gene therapy for intermediate age-related macular degeneration (search).
The partnership is expected to be worth in excess of $1 billion and will allow IKAR-003 (search) to be delivered via minimally invasive intravitreal injection in a doctor's office, enhancing patient access.
IKAR-003 (search) uses a dual-pathway gene therapy approach combining neuroprotection and complement (search) modulation to prevent progression of intermediate AMD, a condition affecting millions worldwide with no approved treatments.
Ikarovec (search) Ltd has secured an exclusive worldwide option agreement with VectorBuilder (search) for novel AAV capsid technology that will enable office-based delivery of its gene therapy candidate IKAR-003 (search) for intermediate age-related macular degeneration (search) (AMD). The strategic partnership, expected to be worth in excess of $1 billion, represents a significant advancement in making gene therapy accessible for early-stage AMD patients.
Novel Delivery Approach for Underserved Patient Population
VectorBuilder (search)'s proprietary capsid technology will allow IKAR-003 (search) to be delivered to the eye via the minimally invasive intravitreal route in a doctor's office, dramatically improving access for patients with intermediate AMD. This patient population, numbering in the millions worldwide, currently has no approved drug treatments and faces significant risk of progressing to geographic atrophy (search) or wet AMD (search), both of which cause irreversible vision loss.
IKAR-003 (search) is designed to prevent disease progression through a one-time injection of an AAV-delivered dual-pathway gene therapy that combines neuroprotection and complement (search) modulation to preserve visual function. This approach targets patients at the earlier, intermediate AMD stage where prevention of disease progression is the primary therapeutic goal.
"Partnering with VectorBuilder (search) on IKAR-003 (search) increases the value of Ikarovec (search)'s pipeline by creating an office-based intravitreally delivered product, ideal for large-scale adoption in the prevention of disease progression setting," said Thomas Ciulla, MD, MBA, President and CEO of Ikarovec. "We have assessed other intravitreal capsid options and are confident that VectorBuilder's technology will provide superior efficacy."
AI-Powered Capsid Engineering Delivers Superior Performance
VectorBuilder (search)'s breakthrough comes from its AI-powered DeepCap platform, which integrates rational design with ultradeep search of AAV sequence space to engineer best-in-class ocular capsids. In non-human primate studies, the company's intravitreally administered capsids demonstrated the ability to target wide areas of the retina and successfully transduce virtually all cells of the macula, showing broader and more robust transduction than current clinical intravitreal capsids.
"By utilizing our AI-powered DeepCap platform that integrates rational design with ultradeep search of AAV sequence space, we were able to engineer best-in-class ocular capsids," said Dr. Bruce Lahn, Founder and Chief Scientist at VectorBuilder (search). "We are confident that our capsid technology, combined with Ikarovec (search)'s innovative dual-pathway therapeutic approach and experienced leadership team, will create a strong foundation for developing transformative therapies for patients with vision-threatening retinal diseases."
Complementary Pipeline Strategy
The IKAR-003 (search) program complements Ikarovec (search)'s lead program IKAR-001 (search), which uses the same dual-pathway approach but targets a different patient population. IKAR-001 remains on track for clinical trial initiation in late 2026 for geographic atrophy (search), using validated subretinal delivery for this advanced stage of disease.
"IKAR-003 (search) uses the same dual-pathway approach as our lead programme, IKAR-001 (search), which remains on track for clinical trial initiation in late 2026 in geographic atrophy (search), using validated subretinal delivery in this advanced stage of disease," Ciulla explained. "We are therefore addressing two distinct patient populations with a delivery approach tailored to each."
Following successful further evaluation of VectorBuilder (search)'s technology, the companies will engage in a strategic partnership under which Ikarovec (search) will be responsible for clinical development and commercialization of IKAR-003 (search). The collaboration leverages VectorBuilder's years of experience working with Ikarovec and deep understanding of the company's technical requirements and therapeutic approach.